Pakistani firm authorised to manufacture hepatitis C oral drug

Published October 6, 2015
A company producing the hepatitis C drug authorised a local company to manufacture the same to lower its price.—Reuters/File
A company producing the hepatitis C drug authorised a local company to manufacture the same to lower its price.—Reuters/File

LAHORE: A research-based US biopharmaceutical company producing the hepatitis C drug in oral form has authorised a Pakistani company to manufacture the same medicine in order to lower its price.

Gilead Sciences recently signed an agreement with Ferozsons Laborato­ries Ltd for the production of hepatitis C drug, sofosbuvir, to help meet its growing demand in the country.

Pakistan is second after Egypt where prevalence of hepatitis C is alarmingly high.

Also read: Hepatitis wonder drug inaccessible to patients

For the purpose, the generic drug company might set its own price, which was expected to be considerably lower than the brand product, and receive a complete technology transfer of the Gilead manufacturing process, enabling it to scale up production, an official told Dawn.

The step has been taken to ensure provision of the drug to an increased number of patients since a majority had limited access to it because of its non-availability on a mass scale.

Earlier, the Gilead had granted the rights to Ferozsons Laboratories to import and market this drug in Pakistan.

The Drug Regulatory Authority Pakistan had registered the drug and approved its price at Rs1,940 per tablet (a pack of 28 tablets for Rs55,000).

Later, the company slashed the price to Rs32,300 per pack but it is still not in the reach of poor patients.

According to medical experts, over 280,000 people fall victim to hepatitis C virus (HCV) in Pakistan every year.

Gregg Alton, executive vice president, Corporate and Medical Affairs at US-based Gilead Sciences, in a letter to the Ministry of National Health Services, Regulation and Coordination, Islamabad, offered his company’s commitment to address the public health needs in the country.

He informed the ministry that since last year Gilead had signed licensing agreements with 14 manufacturing partners, granting them rights to develop and distribute low-cost generic.

“Gilead has signed a new licensing agreement with a Pakistani pharmaceutical firm in an effort to scale up availability of generic versions of life-saving treatments in Pakistan,” Mr Alton said.

Published in Dawn, October 6th , 2015

On a mobile phone? Get the Dawn Mobile App: Apple Store | Google Play

Opinion

Editorial

World Cup squad
24 Sep, 2023

World Cup squad

THE stress was on continuity — trusting and backing players who had been with the team — as Pakistan’s squad...
Mirwaiz freed
24 Sep, 2023

Mirwaiz freed

IT was an emotional return to Srinagar’s Jamia Masjid for Mirwaiz Umar Farooq. After over four years under house...
Beyond lip service
24 Sep, 2023

Beyond lip service

UN SECRETARY GENERAL António Guterres did not mince words at the recently held Climate Ambition Summit: “Humanity...
IMF chief’s advice
Updated 23 Sep, 2023

IMF chief’s advice

Pakistan's prolonged fiscal deficit, surpassing 7pc, stems from the government's reluctance to widen the tax base.
No closure
Updated 23 Sep, 2023

No closure

WHAT is a Pakistani life worth in the eyes of the state? Clearly not enough, if one were to draw a comparison with...
Missing footballers
23 Sep, 2023

Missing footballers

IN the nation’s living memory, Balochistan’s burns have never run dry. The province has grappled with historical...